Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

What is the Advantage of Administering a Beta-Lactam with a Beta-Lactamase Inhibitor?

OCT 13, 2017 | CONTAGION® EDITORIAL STAFF


Amanda Paschke, MD, MSCE, director of Clinical Research, Infectious Diseases, at Merck, breaks down the advantages of administering a beta-lactam in combination with a beta-lactamase inhibitor. Dr. Paschke highlights Merck’s development compound imipenem-relebactam, and explains how relebactam restores susceptibility to imipenem.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x